Valeant Pharmaceuticals International and Turing Pharmaceuticals AG, both under congressional investigation in the US over drug price increases, were focused on making money before helping patients, according to members of Congress.

The pharmaceutical entrepreneur facing US charges of securities fraud said he had been the target of authorities for his drug-price hikes and over-the-top public persona.

Valeant Pharmaceuticals International and Turing Pharmaceuticals are the focus of two probes in Congress seeking to examine why the companies raised the prices of medications sharply after acquiring them.

A US company that raised the price of a drug for treating a deadly parasitic infection by more than 5,000% says it will roll back some of the increase.

The chief executive of a US pharmaceutical company has defended his firm’s decision to raise the price of an Aids medication by more than 5,000% practically overnight.